A Cross-sectional and retrospective chart review study for assessing psoRiasis severitY by absolute PASI score in moderaTe to severe psoriatic pAtients routineLy treated with systemic treatment in Bulgaria, Estonia, Hungary, Latvia, Lithuania, Romania and Russia - The CRYSTAL Study

Study identification

• EU PAS number:
  EUPAS36459
• Study ID:
  45286
• Official title and acronym:
  A Cross-sectional and retrospective chart review study for assessing psoRiasis severitY by absolute PASI score in moderaTe to severe psoriatic pAtients routineLy treated with systemic treatment in Bulgaria, Estonia, Hungary, Latvia, Lithuania, Romania and Russia - The CRYSTAL Study
• DARWIN EU® study:
  No
• Study countries:
  Bulgaria

  Estonia

  Hungary

  Latvia

  Lithuania

  Romania

  Russian Federation
• Study description:
  The main research question is what is the absolute PASI score and associated HRQoL of moderate to severe psoriatic patients routinely managed with systemic treatment for at least 24 weeks under real-world conditions of daily clinical practice in Bulgaria, Estonia, Hungary, Latvia, Lithuania, Romania and Russia.
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 50 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:28/02/2020

Actual:28/02/2020

Study start date

Planned:01/09/2020

Actual:01/09/2020

Date of final study report

Planned:11/02/2022

Actual:02/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AbbVie

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

H20-249